PureTech Health PLC Director/PDMR Shareholding
October 31 2024 - 1:00PM
RNS Regulatory News
RNS Number : 4722K
PureTech Health PLC
31 October 2024
31
October 2024
PureTech Health
plc
PDMR
Notification
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage
biotherapeutics company dedicated to changing the lives of patients
with devastating diseases, announces
the transfer of shares by a non-executive director ("PDMR").
The Company's total issued ordinary
share capital is 257,927,489 shares, 18,506,177 shares of which are
held in treasury by the Company.
PDMR Notification
The information contained in the below notification is
disclosed in accordance with Article 19 of the EU Market Abuse
Regulation.
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a)
|
Name
|
John LaMattina, PhD
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Non-Executive Director
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
PureTech Health plc
|
b)
|
LEI
|
213800LVPDNO2Z9T9I39
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of PureTech Health plc
ISIN GB00BY2Z0H74
|
|
|
b)
|
Nature of the transaction
|
The
transferred shares were held in a charitable trust over which Dr.
LaMattina has control. Dr. LaMattina periodically transfers shares
from this trust to his alma mater, Boston College, as a form of
support.
|
c)
|
Price(s) and volume(s)
|
Individual
|
Price
|
Volume
|
John LaMattina
|
Nil
|
52,640
|
|
e)
|
Date of the transaction
|
29 October 2024
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
About PureTech Health
PureTech is a clinical-stage biotherapeutics
company dedicated to giving life to new classes of medicine to
change the lives of patients with devastating diseases. The Company
has created a broad and deep pipeline through its experienced
research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded Entities. PureTech's
R&D engine has resulted in the development of 29 therapeutics
and therapeutic candidates, including three that have been approved
by the U.S. Food and Drug Administration. A number of these
programs are being advanced by PureTech or its Founded Entities in
various indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points.
For more information,
visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHEFLFXZBLEFBQ
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Nov 2023 to Nov 2024